Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children

right heart catheterization
endothelin
hypertension
selexipag
endothelin receptor antagonist
  • 34 views
  • 10 Sep, 2021
  • 94 locations
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).

  • 0 views
  • 10 Sep, 2021
  • 45 locations
A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study

The purpose of this study is to assess the long-term safety of selexipag while providing continued selexipag treatment for participants who were previously enrolled in an Actelion-sponsored

  • 0 views
  • 12 Sep, 2021
  • 15 locations
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH

pulmonary arterial hypertension
selexipag
endarterectomy
  • 27 views
  • 09 Sep, 2021
  • 289 locations
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH). The aim of the

  • 0 views
  • 12 Sep, 2021
  • 77 locations
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in

heart disease
endothelin
endothelin receptor antagonist
right heart catheterization
primary pulmonary hypertension
  • 201 views
  • 10 Sep, 2021
  • 154 locations
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension

for Sch-PAH patients, since this etiology was not included in the pivotal PAH trials. One of the most promising therapies for the treatment of PAH to emerge in recent years is selexipag, an oral IP

phosphodiesterase-5 (pde-5) inhibitor
endothelin receptor antagonist
endothelin
right ventricular failure
pulmonary arterial hypertension
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag

The purpose of the study is to evaluate the change from baseline to 12 months after study enrollment in the number of the following non-invasive risk criteria: World Health Organization Functional Class (WHO/FC), 6-minute walk distance (6MWD), Brain Natriuretic Peptide (BNP) or N-terminal pro-brain Natriuretic Peptide (NT-proBNP).

  • 0 views
  • 09 Sep, 2021
  • 35 locations